• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023

    2/24/23 10:00:48 AM ET
    $AMSF
    $BMEA
    $BOWL
    $CCCC
    Property-Casualty Insurers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMSF alert in real time by email

    Upgrades

    According to UBS, the prior rating for Vipshop Holdings Ltd (NYSE:VIPS) was changed from Neutral to Buy. For the fourth quarter, Vipshop Holdings had an EPS of $0.53, compared to year-ago quarter EPS of $0.41. At the moment, the stock has a 52-week-high of $16.18 and a 52-week-low of $5.75. Vipshop Holdings closed at $13.62 at the end of the last trading period.

    Canaccord Genuity upgraded the previous rating for Kratos Defense & Security Solutions Inc (NASDAQ:KTOS) from Hold to Buy. For the fourth quarter, Kratos Defense & Security had an EPS of $0.08, compared to year-ago quarter EPS of $0.11. The stock has a 52-week-high of $22.26 and a 52-week-low of $8.90. At the end of the last trading period, Kratos Defense & Security closed at $11.47.

    According to TD Securities, the prior rating for Newmont Corp (NYSE:NEM) was changed from Hold to Buy. In the fourth quarter, Newmont showed an EPS of $0.44, compared to $0.78 from the year-ago quarter. The current stock performance of Newmont shows a 52-week-high of $86.37 and a 52-week-low of $37.45. Moreover, at the end of the last trading period, the closing price was at $44.26.

    For Block Inc (NYSE:SQ), Evercore ISI Group upgraded the previous rating of Underperform to In-Line. Block earned $0.22 in the fourth quarter, compared to $0.27 in the year-ago quarter. At the moment, the stock has a 52-week-high of $149.00 and a 52-week-low of $51.34. Block closed at $74.15 at the end of the last trading period.

    According to Benchmark, the prior rating for NeoGenomics Inc (NASDAQ:NEO) was changed from Hold to Buy. In the fourth quarter, NeoGenomics showed an EPS of $0.06, compared to $0.14 from the year-ago quarter. The current stock performance of NeoGenomics shows a 52-week-high of $21.94 and a 52-week-low of $6.00. Moreover, at the end of the last trading period, the closing price was at $16.63.

    CLSA upgraded the previous rating for Vipshop Holdings Ltd (NYSE:VIPS) from Outperform to Buy. Vipshop Holdings earned $0.53 in the fourth quarter, compared to $0.41 in the year-ago quarter. The stock has a 52-week-high of $16.18 and a 52-week-low of $5.75. At the end of the last trading period, Vipshop Holdings closed at $13.62.

    Jefferies upgraded the previous rating for Youdao Inc (NYSE:DAO) from Hold to Buy. Youdao earned $0.04 in the fourth quarter, compared to $0.21 in the year-ago quarter. The stock has a 52-week-high of $12.55 and a 52-week-low of $3.03. At the end of the last trading period, Youdao closed at $8.00.

    For W.W. Grainger Inc (NYSE:GWW), RBC Capital upgraded the previous rating of Underperform to Sector Perform. For the fourth quarter, W.W. Grainger had an EPS of $7.14, compared to year-ago quarter EPS of $5.44. The current stock performance of W.W. Grainger shows a 52-week-high of $685.23 and a 52-week-low of $440.48. Moreover, at the end of the last trading period, the closing price was at $657.94.

    RBC Capital upgraded the previous rating for LyondellBasell Industries NV (NYSE:LYB) from Sector Perform to Outperform. In the fourth quarter, LyondellBasell Industries showed an EPS of $1.29, compared to $3.63 from the year-ago quarter. At the moment, the stock has a 52-week-high of $117.22 and a 52-week-low of $71.46. LyondellBasell Industries closed at $94.65 at the end of the last trading period.

    For Century Aluminum Co (NASDAQ:CENX), Wolfe Research upgraded the previous rating of Underperform to Peer Perform. In the fourth quarter, Century Aluminum showed an EPS of $0.31, compared to $0.17 from the year-ago quarter. The stock has a 52-week-high of $30.36 and a 52-week-low of $5.27. At the end of the last trading period, Century Aluminum closed at $10.36.

    See all analyst ratings upgrades.

    Downgrades

    BMO Capital downgraded the previous rating for Wingstop Inc (NASDAQ:WING) from Outperform to Market Perform. Wingstop earned $0.60 in the fourth quarter, compared to $0.24 in the year-ago quarter. The stock has a 52-week-high of $193.74 and a 52-week-low of $67.67. At the end of the last trading period, Wingstop closed at $174.23.

    SMBC Nikko downgraded the previous rating for Jounce Therapeutics Inc (NASDAQ:JNCE) from Outperform to Neutral. In the third quarter, Jounce Therapeutics showed an EPS of $0.60, compared to $0.59 from the year-ago quarter. The current stock performance of Jounce Therapeutics shows a 52-week-high of $7.94 and a 52-week-low of $0.58. Moreover, at the end of the last trading period, the closing price was at $1.10.

    SVB Leerink downgraded the previous rating for Moderna Inc (NASDAQ:MRNA) from Market Perform to Underperform. In the fourth quarter, Moderna showed an EPS of $3.61, compared to $11.29 from the year-ago quarter. The stock has a 52-week-high of $217.25 and a 52-week-low of $115.03. At the end of the last trading period, Moderna closed at $147.57.

    According to B of A Securities, the prior rating for OGE Energy Corp (NYSE:OGE) was changed from Buy to Neutral. For the fourth quarter, OGE Energy had an EPS of $0.25, compared to year-ago quarter EPS of $0.27. The current stock performance of OGE Energy shows a 52-week-high of $42.91 and a 52-week-low of $33.28. Moreover, at the end of the last trading period, the closing price was at $37.27.

    According to Goldman Sachs, the prior rating for YETI Holdings Inc (NYSE:YETI) was changed from Buy to Neutral. In the fourth quarter, YETI Holdings showed an EPS of $0.78, compared to $0.87 from the year-ago quarter. The stock has a 52-week-high of $65.46 and a 52-week-low of $27.86. At the end of the last trading period, YETI Holdings closed at $39.31.

    Ladenburg Thalmann downgraded the previous rating for New York Mortgage Trust Inc (NASDAQ:NYMT) from Buy to Neutral. For the fourth quarter, New York Mortgage Trust had an EPS of $0.13, compared to year-ago quarter EPS of $0.06. The stock has a 52-week-high of $3.75 and a 52-week-low of $2.07. At the end of the last trading period, New York Mortgage Trust closed at $2.73.

    According to Maxim Group, the prior rating for Unisys Corp (NYSE:UIS) was changed from Buy to Hold. Unisys earned $1.22 in the fourth quarter, compared to $0.51 in the year-ago quarter. The stock has a 52-week-high of $23.10 and a 52-week-low of $3.93. At the end of the last trading period, Unisys closed at $5.70.

    Needham downgraded the previous rating for Upland Software Inc (NASDAQ:UPLD) from Buy to Hold. Upland Software earned $0.37 in the fourth quarter, compared to $0.60 in the year-ago quarter. The current stock performance of Upland Software shows a 52-week-high of $20.23 and a 52-week-low of $6.26. Moreover, at the end of the last trading period, the closing price was at $8.73.

    According to Craig-Hallum, the prior rating for Vicor Corp (NASDAQ:VICR) was changed from Buy to Hold. In the fourth quarter, Vicor showed an EPS of $0.18, compared to $0.20 from the year-ago quarter. The current stock performance of Vicor shows a 52-week-high of $100.40 and a 52-week-low of $42.90. Moreover, at the end of the last trading period, the closing price was at $56.32.

    According to Raymond James, the prior rating for WideOpenWest Inc (NYSE:WOW) was changed from Strong Buy to Outperform. For the fourth quarter, WideOpenWest had an EPS of $0.15, compared to year-ago quarter EPS of $0.01. The current stock performance of WideOpenWest shows a 52-week-high of $22.94 and a 52-week-low of $8.57. Moreover, at the end of the last trading period, the closing price was at $12.40.

    According to Baird, the prior rating for Domino's Pizza Inc (NYSE:DPZ) was changed from Outperform to Neutral. In the fourth quarter, Domino's Pizza showed an EPS of $4.43, compared to $4.25 from the year-ago quarter. At the moment, the stock has a 52-week-high of $448.99 and a 52-week-low of $299.41. Domino's Pizza closed at $307.86 at the end of the last trading period.

    Baird downgraded the previous rating for Stericycle Inc (NASDAQ:SRCL) from Outperform to Neutral. In the fourth quarter, Stericycle showed an EPS of $0.60, compared to $0.38 from the year-ago quarter. The stock has a 52-week-high of $59.89 and a 52-week-low of $39.63. At the end of the last trading period, Stericycle closed at $48.86.

    Cantor Fitzgerald downgraded the previous rating for Root Inc (NASDAQ:ROOT) from Overweight to Neutral. In the fourth quarter, Root showed an EPS of $4.13, compared to $7.92 from the year-ago quarter. At the moment, the stock has a 52-week-high of $21.38 and a 52-week-low of $0.94. Root closed at $5.77 at the end of the last trading period.

    For Venator Materials PLC (NYSE:VNTR), Deutsche Bank downgraded the previous rating of Buy to Hold. Venator Materials earned $0.20 in the fourth quarter, compared to $0.05 in the year-ago quarter. The stock has a 52-week-high of $2.78 and a 52-week-low of $0.41. At the end of the last trading period, Venator Materials closed at $0.49.

    For Nektar Therapeutics (NASDAQ:NKTR), Jefferies downgraded the previous rating of Hold to Underperform. Nektar Therapeutics earned $0.31 in the third quarter, compared to $0.70 in the year-ago quarter. The current stock performance of Nektar Therapeutics shows a 52-week-high of $11.39 and a 52-week-low of $1.99. Moreover, at the end of the last trading period, the closing price was at $2.96.

    According to JP Morgan, the prior rating for C4 Therapeutics Inc (NASDAQ:CCCC) was changed from Neutral to Underweight. For the fourth quarter, C4 Therapeutics had an EPS of $0.76, compared to year-ago quarter EPS of $0.31. At the moment, the stock has a 52-week-high of $26.80 and a 52-week-low of $4.84. C4 Therapeutics closed at $6.02 at the end of the last trading period.

    For Infinity Pharmaceuticals Inc (NASDAQ:INFI), Piper Sandler downgraded the previous rating of Overweight to Neutral. In the third quarter, Infinity Pharmaceuticals showed an EPS of $0.12, compared to $0.12 from the year-ago quarter. The stock has a 52-week-high of $1.76 and a 52-week-low of $0.28. At the end of the last trading period, Infinity Pharmaceuticals closed at $0.28.

    For Domino's Pizza Inc (NYSE:DPZ), Citigroup downgraded the previous rating of Buy to Neutral. For the fourth quarter, Domino's Pizza had an EPS of $4.43, compared to year-ago quarter EPS of $4.25. The current stock performance of Domino's Pizza shows a 52-week-high of $448.99 and a 52-week-low of $299.41. Moreover, at the end of the last trading period, the closing price was at $307.86.

    For CURO Group Holdings Corp (NYSE:CURO), Credit Suisse downgraded the previous rating of Outperform to Neutral. In the fourth quarter, CURO Group Holdings showed an EPS of $0.80, compared to $0.29 from the year-ago quarter. The current stock performance of CURO Group Holdings shows a 52-week-high of $13.70 and a 52-week-low of $2.96. Moreover, at the end of the last trading period, the closing price was at $3.70.

    See all analyst ratings downgrades.

    Initiations

    With a Buy rating, Citigroup initiated coverage on Biomea Fusion Inc (NASDAQ:BMEA). The price target seems to have been set at $20.00 for Biomea Fusion. In the third quarter, Biomea Fusion showed an EPS of $0.78, compared to $0.43 from the year-ago quarter. The current stock performance of Biomea Fusion shows a 52-week-high of $14.20 and a 52-week-low of $2.84. Moreover, at the end of the last trading period, the closing price was at $11.00.

    With a Buy rating, Janney Montgomery Scott initiated coverage on Employers Holdings Inc (NYSE:EIG). The price target seems to have been set at $50.00 for Employers Holdings. In the fourth quarter, Employers Holdings showed an EPS of $1.25, compared to $1.06 from the year-ago quarter. At the moment, the stock has a 52-week-high of $46.73 and a 52-week-low of $32.58. Employers Holdings closed at $43.31 at the end of the last trading period.

    Janney Montgomery Scott initiated coverage on ProAssurance Corp (NYSE:PRA) with a Neutral rating. The price target for ProAssurance is set to $21.00. For the third quarter, ProAssurance had an EPS of $0.06, compared to year-ago quarter EPS of $0.25. The current stock performance of ProAssurance shows a 52-week-high of $27.55 and a 52-week-low of $16.90. Moreover, at the end of the last trading period, the closing price was at $19.65.

    With a Neutral rating, Janney Montgomery Scott initiated coverage on AMERISAFE Inc (NASDAQ:AMSF). The price target seems to have been set at $58.00 for AMERISAFE. For the fourth quarter, AMERISAFE had an EPS of $0.84, compared to year-ago quarter EPS of $0.00. At the moment, the stock has a 52-week-high of $60.49 and a 52-week-low of $44.06. AMERISAFE closed at $54.34 at the end of the last trading period.

    Piper Sandler initiated coverage on Orchestra BioMed Holdings Inc (NASDAQ:OBIO) with an Overweight rating. The price target for Orchestra BioMed Hldgs is set to $15.00. The stock has a 52-week-high of $12.43 and a 52-week-low of $7.49. At the end of the last trading period, Orchestra BioMed Hldgs closed at $10.30.

    With a Buy rating, Craig-Hallum initiated coverage on Bowlero Corp (NYSE:BOWL). The price target seems to have been set at $24.00 for Bowlero. In the second quarter, Bowlero showed an EPS of $0.20, compared to $0.25 from the year-ago quarter. The current stock performance of Bowlero shows a 52-week-high of $15.71 and a 52-week-low of $8.19. Moreover, at the end of the last trading period, the closing price was at $15.00.

    Goldman Sachs initiated coverage on Erasca Inc (NASDAQ:ERAS) with a Buy rating. The price target for Erasca is set to $10.00. In the third quarter, Erasca showed an EPS of $0.29, compared to $0.46 from the year-ago quarter. The stock has a 52-week-high of $12.80 and a 52-week-low of $3.51. At the end of the last trading period, Erasca closed at $3.57.

    With an Overweight rating, Barclays initiated coverage on MGM Resorts International (NYSE:MGM). The price target seems to have been set at $59.00 for MGM Resorts Intl. MGM Resorts Intl earned $1.53 in the fourth quarter, compared to $0.12 in the year-ago quarter. The current stock performance of MGM Resorts Intl shows a 52-week-high of $45.64 and a 52-week-low of $26.41. Moreover, at the end of the last trading period, the closing price was at $43.15.

    Scotiabank initiated coverage on HashiCorp Inc (NASDAQ:HCP) with a Sector Perform rating. The price target for HashiCorp is set to $34.00. The stock has a 52-week-high of $60.03 and a 52-week-low of $21.50. At the end of the last trading period, HashiCorp closed at $30.01.

    Piper Sandler initiated coverage on Integer Holdings Corp (NYSE:ITGR) with an Overweight rating. The price target for Integer Holdings is set to $85.00. Integer Holdings earned $1.11 in the fourth quarter, compared to $0.99 in the year-ago quarter. At the moment, the stock has a 52-week-high of $88.58 and a 52-week-low of $50.05. Integer Holdings closed at $73.80 at the end of the last trading period.

    See all analyst ratings initiations.

    Get the next $AMSF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMSF
    $BMEA
    $BOWL
    $CCCC

    CompanyDatePrice TargetRatingAnalyst
    Nektar Therapeutics
    $NKTR
    2/10/2026Mkt Perform → Outperform
    William Blair
    Wingstop Inc.
    $WING
    2/10/2026$285.00Buy → Hold
    TD Cowen
    Wingstop Inc.
    $WING
    2/10/2026$325.00Strong Buy → Outperform
    Raymond James
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Erasca Inc.
    $ERAS
    1/27/2026$16.00Outperform
    Mizuho
    W.W. Grainger Inc.
    $GWW
    1/27/2026$1250.00Perform → Outperform
    Oppenheimer
    Kratos Defense & Security Solutions Inc.
    $KTOS
    1/22/2026$99.00Neutral
    Piper Sandler
    OGE Energy Corp
    $OGE
    1/20/2026$39.00Equal Weight → Underweight
    Wells Fargo
    More analyst ratings

    $AMSF
    $BMEA
    $BOWL
    $CCCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Erdtmann Rainer M bought $42,999 worth of shares (30,000 units at $1.43), increasing direct ownership by 4% to 723,027 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/15/25 4:15:04 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interim CEO Hitchcock Michael J.M. bought $99,180 worth of shares (100,000 units at $0.99), increasing direct ownership by 667% to 115,000 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/4/25 4:15:03 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Erdtmann Rainer M bought $54,552 worth of shares (50,000 units at $1.09), increasing direct ownership by 8% to 693,027 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/2/25 4:15:02 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMSF
    $BMEA
    $BOWL
    $CCCC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMSF
    $BMEA
    $BOWL
    $CCCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nektar Therapeutics upgraded by William Blair

    William Blair upgraded Nektar Therapeutics from Mkt Perform to Outperform

    2/10/26 11:48:14 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wingstop downgraded by TD Cowen with a new price target

    TD Cowen downgraded Wingstop from Buy to Hold and set a new price target of $285.00

    2/10/26 8:00:55 AM ET
    $WING
    Restaurants
    Consumer Discretionary

    Wingstop downgraded by Raymond James with a new price target

    Raymond James downgraded Wingstop from Strong Buy to Outperform and set a new price target of $325.00

    2/10/26 8:00:55 AM ET
    $WING
    Restaurants
    Consumer Discretionary

    $AMSF
    $BMEA
    $BOWL
    $CCCC
    SEC Filings

    View All

    SEC Form 8-K filed by Orchestra BioMed Holdings Inc.

    8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

    2/13/26 5:00:32 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Wingstop Inc.

    SCHEDULE 13G/A - Wingstop Inc. (0001636222) (Subject)

    2/13/26 10:04:29 AM ET
    $WING
    Restaurants
    Consumer Discretionary

    Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Moderna, Inc. (0001682852) (Filer)

    2/13/26 7:02:14 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMSF
    $BMEA
    $BOWL
    $CCCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jarvis Scot B sold $442,000 worth of shares (5,000 units at $88.40), decreasing direct ownership by 5% to 95,417 units (SEC Form 4)

    4 - KRATOS DEFENSE & SECURITY SOLUTIONS, INC. (0001069258) (Issuer)

    2/13/26 7:06:35 PM ET
    $KTOS
    Military/Government/Technical
    Industrials

    SEC Form 4 filed by Principal Accounting Officer Aiello Joshua

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    2/13/26 5:02:11 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Sherman Darren was granted 397,000 shares, increasing direct ownership by 47% to 1,237,569 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    2/13/26 5:01:46 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $AMSF
    $BMEA
    $BOWL
    $CCCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public offering of $460 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Nektar sold 7,637,931 shares of common stock in the offering, which includes 1,034,482 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering, and 293,103 pre-funded warrants. The shares of common stock were sold at a public offering price

    2/13/26 4:15:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEW HOPE, Pa., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on February 12, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 120,000 shares of the Company's common stock to nine newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new employee entering employment w

    2/13/26 4:05:00 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Kratos and Champion Tire & Wheel Expand Automated Truck Platooning for NASCAR 2026 Season

    SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS), a Technology Company in the Defense, National Security, and Global Markets, today announced continued support of Champion Tire & Wheel's NASCAR logistics for the 2026 season. This will be further advancement of Kratos' automated truck platooning and logistics automation technologies, demonstrating scalable autonomy in demanding, real-world operations. The fast-paced, time-critical environment of race logistics offers an ideal proving ground for autonomy designed to enhance coordination, consistency, and efficiency. Kratos' auto-platooning capability pairs a human-driven lead vehicle with

    2/13/26 9:00:00 AM ET
    $KTOS
    Military/Government/Technical
    Industrials

    $AMSF
    $BMEA
    $BOWL
    $CCCC
    Leadership Updates

    Live Leadership Updates

    View All

    BETMGM FY 2025 BUSINESS UPDATE

    Successful strategic execution delivered stronger than expected 2025 performance and EBITDA inflection JERSEY CITY, N.J., Feb. 4, 2026 /PRNewswire/ -- BetMGM LLC ("BetMGM"), a leading sports betting and iGaming operator across North America, jointly owned by MGM Resorts International (NYSE:MGM) ("MGM Resorts") and Entain plc (LSE: ENT) ("Entain"), is today providing an update on its Fiscal Year 2025 ("FY 2025") performance. FY 2025 performance exceeded expectations, reflecting benefit of a full year of strategic initiatives driving strong underlying growth in both iGaming and

    2/4/26 7:00:00 AM ET
    $MGM
    Hotels/Resorts
    Consumer Discretionary

    NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

    – Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million – – Announces Chief Financial Officer transition – NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue For the fourth quarter of 2025, NeoGenomics expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%. For the full-year 2025, Neo

    1/12/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. "Jack" Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service. Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive, commercial, and operational experience and a track record of success in the diagnostics and lab services businesses. He most recently served as President, Chief Executive Officer and Board Director of Meridian Bioscience, a fully i

    12/30/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $AMSF
    $BMEA
    $BOWL
    $CCCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vicor Corporation

    SC 13G/A - VICOR CORP (0000751978) (Subject)

    12/4/24 2:38:58 PM ET
    $VICR
    Industrial Machinery/Components
    Technology

    Amendment: SEC Form SC 13G/A filed by Vipshop Holdings Limited

    SC 13G/A - Vipshop Holdings Ltd (0001529192) (Subject)

    11/15/24 6:37:28 AM ET
    $VIPS
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

    SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 7:53:04 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMSF
    $BMEA
    $BOWL
    $CCCC
    Financials

    Live finance-specific insights

    View All

    Kratos Defense & Security Solutions Schedules Fourth Quarter and Fiscal Year 2025 Earnings Conference Call for Monday, February 23rd

    SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS), a Technology Company in the Defense, National Security and Global Markets, announced today that it will publish financial results for the fourth quarter and fiscal year 2025 after the close of market on Monday, February 23rd. Management will discuss the Company's operations and financial results in a conference call beginning at 2:00 p.m. Pacific (5:00 p.m. Eastern). The call will be available at www.kratosdefense.com. Participants may register for the call using this Online Form. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN that ca

    2/13/26 8:00:00 AM ET
    $KTOS
    Military/Government/Technical
    Industrials

    Vipshop to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GUANGZHOU, China, Feb. 13, 2026 /PRNewswire/ -- Vipshop Holdings Limited (NYSE:VIPS), a leading online discount retailer for brands in China ("Vipshop" or the "Company"), today announced that it plans to release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, before the US market open. The Company will hold a conference call on Thursday, February 26, 2026 at 7:00 am US Eastern Time, 8:00 pm Beijing Time to discuss the financial results. All participants wishing to join the conference call must pre-register online using the link provided below. Registration Link: https://register-conf.media-server.com/register/BId8a721cb0cc8420cab7858dc569d1e68 Once pr

    2/13/26 5:00:00 AM ET
    $VIPS
    Catalog/Specialty Distribution
    Consumer Discretionary

    Clairvest Reports Fiscal 2026 Third Quarter Results

    TORONTO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Clairvest Group Inc. (TSX:CVG) today reported results for the fiscal 2026 third quarter and nine months ended December 31, 2025. (All figures are in Canadian dollars unless otherwise stated) Highlights December 31, 2025 book value was $1,255 million or $91.66 per share compared with $1,154 million or $83.92 per share as at September 30, 2025, up 9% in the quarterNet income for the quarter ended December 31, 2025 was $105.1 million or $7.65 per share, primarily due to two investment realizations as described belowNet income for the nine months ended December 31, 2025 was $49.7 million, or $3.74 per shareClairvest and Clairvest Equity Partners VI

    2/11/26 5:05:00 PM ET
    $MGM
    Hotels/Resorts
    Consumer Discretionary